FUJIFILM Biotechnologies, a CDMO for biologics, vaccines, and advanced therapies, opened its expanded site in Teesside, UK. The expansion was funded through an investment of approximately £400 million from FUJIFILM Corp. It includes the opening of a single-use biopharmaceutical CDMO facility, located at the existing FUJIFILM Biotechnologies site. 


The UK expansion introduces 2,000 L and 5,000 L single-use bioreactors with a total capacity up to 19,000 L to provide small- and mid-scale antibody manufacturing, with the  flexibility to expand as needed. The 110,000 sq. ft. manufacturing facility will be operational in the first half of 2026. 


In parallel, the opening of the Bioprocess Innovation Centre UK, provides lab services for both high-throughput, and continuous process development capabilities, and will operate as a global center of excellence for biomanufacturing and process development. The 102,200 sq. ft. facility doubles the campus’ existing lab footprint and complements the sites’ expanded GMP manufacturing capabilities. 


These investments enhance the supply chain agility of FUJIFILM Biotechnologies’ global manufacturing network and expand its capacity to develop and produce complex medicines for biopharmaceutical companies. 

“This site provides pharmaceutical and biotechnology partners with enhanced scalability, speed to market, and cross-site technology transfer, helping to ensure reliable medicine supply for patients in the UK and globally,” said Lars Petersen, president and chief executive officer, FUJIFILM Biotechnologies. “This represents the first small and mid-scale manufacturing site in our global kojoX ecosystem, which provides our partners with supply chain flexibility and agility. In leveraging kojoX across our sites, we are creating a framework where our partners can easily scale up and out from process development through clinical and commercial.”